This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates
by Zacks Equity Research
Agios' (AGIO) earnings and revenues miss estimates in the fourth quarter of 2023. Revenues from its sole marketed drug, Pyrukynd, rise year over year.
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -4.88% and 9.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More
by Zacks Equity Research
Let's look at five biotech/drug companies, ALNY, BPMC, AGIO, CORT and RARE, slated to release quarterly results on Feb 15.
Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study
by Zacks Equity Research
Data from a late-stage study shows that non-transfusion-dependent thalassemia patients who received Agios' (AGIO) mitapivat demonstrated a statistically significant increase in hemoglobin response.
Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More
by Zacks Equity Research
Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.
Agios Pharmaceuticals (AGIO) Soars 5.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Agios (AGIO) Meets Clinical Proof-of-Concept in Anemia Treatment
by Zacks Equity Research
Data from a phase IIa study shows that 40% of patients with low transfusion burden who received Agios' (AGIO) investigational PK activator drug met the transfusion independence endpoint.
Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales
by Zacks Equity Research
Agios' (AGIO) Q3 earnings beat estimates, but sales miss the same.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Why Is Haemonetics (HAE) Down 1.9% Since Last Earnings Report?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam (ALNY) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in collaboration with other pharma bigwigs.
Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Agios (AGIO) reports narrower-than-expected loss in the second quarter of 2023. The revenues are in line with the Zacks Consensus Estimate.
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.63% and 0.63%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Envista (NVST) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of 4.88% and 1.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Top Research Reports for Microsoft, Salesforce & United Parcel Service
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Salesforce, Inc. (CRM) and United Parcel Service, Inc. (UPS).
Should You Buy Agios Pharmaceuticals (AGIO) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Wall Street Analysts Think Agios Pharmaceuticals (AGIO) Could Surge 42.06%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 42.1% in Agios Pharmaceuticals (AGIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are Medical Stocks Lagging Agios Pharmaceuticals (AGIO) This Year?
by Zacks Equity Research
Here is how Agios Pharmaceuticals (AGIO) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.
Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint
by Zacks Equity Research
Agios' (AGIO) mid-stage, label expansion study of mitapivat meets its primary endpoint. The data from the study supports AGIO's decision to proceed with the phase III portion of the investigation.
Wall Street Analysts Believe Agios Pharmaceuticals (AGIO) Could Rally 39.16%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 39.2% in Agios Pharmaceuticals (AGIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Agios Pharmaceuticals (AGIO): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Does Agios Pharmaceuticals (AGIO) Have the Potential to Rally 34.83% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 34.8% in Agios Pharmaceuticals (AGIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.